Accelerating Advancement In Gene Therapy By Improving Downstream Purification Of Viral Vectors

Over the past decade, gene therapy applications and their importance in the biopharmaceutical industry have been increasing. The non-pathogenic adeno-associated virus (AAV) has emerged as the vector of choice for many therapies but purification of biologically active viral vectors for large-scale commercial use is a challenge. Thermo Fisher Scientific has developed  downstream purification solutions, enabling the scale-up of viral vector production.

VIRAL VECTOR PURIFICATION CHALLENGES

• Multiple chromatography steps & concentration needed due to challenging feedstock
• Long process development lead times
• Cumulative yield losses with each unit operation